Last reviewed · How we verify
TransCon PTH
TransCon PTH is a long-acting parathyroid hormone analogue designed to mimic the natural physiological profile of endogenous parathyroid hormone.
TransCon PTH is a long-acting parathyroid hormone analogue designed to mimic the natural physiological profile of endogenous parathyroid hormone. Used for Treatment of osteoporosis in men and women.
At a glance
| Generic name | TransCon PTH |
|---|---|
| Sponsor | Visen Pharmaceuticals (Shanghai) Co., Ltd. |
| Drug class | PTH analogue |
| Target | PTH receptor |
| Modality | Small molecule |
| Therapeutic area | Bone disorders |
| Phase | Phase 3 |
Mechanism of action
TransCon PTH is a prodrug that is designed to provide a sustained release of parathyroid hormone, mimicking the natural physiological profile of endogenous parathyroid hormone. This allows for a more consistent and predictable effect on bone metabolism, potentially reducing the risk of osteoporosis and fractures.
Approved indications
- Treatment of osteoporosis in men and women
Common side effects
- Nausea
- Headache
- Injection site reaction
Key clinical trials
- A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism (PHASE3)
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism (PHASE3)
- Palopegteriparatide in Chronic Hypoparathyroidism
- PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism (PHASE3)
- Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TransCon PTH CI brief — competitive landscape report
- TransCon PTH updates RSS · CI watch RSS
- Visen Pharmaceuticals (Shanghai) Co., Ltd. portfolio CI